6:15 PM
 | 
Aug 17, 2009
 |  BC Extra  |  Company News

Protalix's prGCD to be available to Gaucher's patients

FDA approved a treatment protocol for an open-label trial that would provide expanded patient access to prGCD from Protalix Biotherapeutics Inc. (NYSE-A:PLX). The move is designed to help manage the...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >